Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBO-8520,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BridgeBio Oncology Receives FDA Fast Track for BBO-8520 in NSCLC
Details : BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.
Product Name : BBO-8520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : BBO-8520,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBO-10203,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BridgeBio Doses First Patient with BBO-10203 in Phase 1 BREAKER-101 Trial
Details : BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction between RAS and PI3Kα to inhibit PI3Kα-AKT signaling in tumors.
Product Name : BBO-10203
Product Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2024
Lead Product(s) : BBO-10203,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
